Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication : A Randomized Control Trial
Copyright: © Pakistan Journal of Medical Sciences..
Objectives: To compare the efficacy of Vonoprazan based dual treatment versus PPI based treatment for the eradication of Helicobacter pylori infection.
Methods: A randomized controlled trial was conducted in Department of Medicine/Gastroenterology Ruth KM Pfau Civil Hospital, DMC during the period of 22 June to 21 September 2021. Sample size was calculated as 96 in each Group. All patients of age 18-75 years with Helicobacter Pylori Infection were inducted and randomly allocated to two groups. Group-A: were given Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg all medications were given twice daily for two weeks. Group-B were given Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg (Vonozon©, m/s Getz Pharma, Pakistan) twice daily for two weeks. Confirmation of Hp eradication was done by stool Hp antigen test four weeks after completion of treatment. Nine and four patients were lost to follow-up in Group-A & B respectively. Analysis was conducted on 87 patients in Group-A and 92 patients in Group-B.
Results: Out of eighty-seven patients in Group-A and ninety-two patients in Group-B, 73 (83.9%) patients in Group-A and 86 (93.5%) patients in Group-B had negative H pylori result respectively after treatment (p = .042). Significantly higher frequencies of adverse events were observed in Group-A as compared to Group-B in nausea/vomiting (p = .035) and bloating (p = .045).
Conclusion: VA-dual provides an acceptable eradication rate with fewer adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Pakistan journal of medical sciences - 38(2022), 4Part-II vom: 17. März, Seite 965-969 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zuberi, Bader Faiyaz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amoxicillin |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12669/pjms.38.4.5436 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341568899 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341568899 | ||
| 003 | DE-627 | ||
| 005 | 20231226012100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12669/pjms.38.4.5436 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341568899 | ||
| 035 | |a (NLM)35634610 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zuberi, Bader Faiyaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication |b A Randomized Control Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Pakistan Journal of Medical Sciences. | ||
| 520 | |a Objectives: To compare the efficacy of Vonoprazan based dual treatment versus PPI based treatment for the eradication of Helicobacter pylori infection | ||
| 520 | |a Methods: A randomized controlled trial was conducted in Department of Medicine/Gastroenterology Ruth KM Pfau Civil Hospital, DMC during the period of 22 June to 21 September 2021. Sample size was calculated as 96 in each Group. All patients of age 18-75 years with Helicobacter Pylori Infection were inducted and randomly allocated to two groups. Group-A: were given Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg all medications were given twice daily for two weeks. Group-B were given Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg (Vonozon©, m/s Getz Pharma, Pakistan) twice daily for two weeks. Confirmation of Hp eradication was done by stool Hp antigen test four weeks after completion of treatment. Nine and four patients were lost to follow-up in Group-A & B respectively. Analysis was conducted on 87 patients in Group-A and 92 patients in Group-B | ||
| 520 | |a Results: Out of eighty-seven patients in Group-A and ninety-two patients in Group-B, 73 (83.9%) patients in Group-A and 86 (93.5%) patients in Group-B had negative H pylori result respectively after treatment (p = .042). Significantly higher frequencies of adverse events were observed in Group-A as compared to Group-B in nausea/vomiting (p = .035) and bloating (p = .045) | ||
| 520 | |a Conclusion: VA-dual provides an acceptable eradication rate with fewer adverse events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amoxicillin | |
| 650 | 4 | |a Clarithromycin | |
| 650 | 4 | |a Helicobacter Pylori | |
| 650 | 4 | |a Proton Pump Inhibitors | |
| 650 | 4 | |a Vonoprazan | |
| 700 | 1 | |a Ali, Faiza Sadaqat |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Tazeen |e verfasserin |4 aut | |
| 700 | 1 | |a Bader, Nimrah |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Sana Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Saleem, Anoshia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pakistan journal of medical sciences |d 2007 |g 38(2022), 4Part-II vom: 17. März, Seite 965-969 |w (DE-627)NLM182942562 |x 1682-024X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:4Part-II |g day:17 |g month:03 |g pages:965-969 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12669/pjms.38.4.5436 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 4Part-II |b 17 |c 03 |h 965-969 | ||